Impact of antidiabetic therapy on the risk of cardiovascular diseases and their complications in patients with type 2 diabetes mellitus


如何引用文章

全文:

详细

In Russia, diabetes mellitus afflicts 8 million people, 90% of them had type 2 diabetes mellitus (T2DM) and this figure is growing steadily. At the same time there is a rise in the incidence of macrovascular events (unstable angina pectoris, myocardial infarction). Coronary heart disease and its attack are a major cause of death in the developed countries, including Russia. To prevent chronic complications of DM is likely to be the most urgent task of not only modern diabetology, but also medical science as a whole. In this connection, of great value are the results of a few large international randomized controlled studies, the main objective of which was to evaluate the impact of the rate of blood glucose control on the incidence and outcomes of cardiovascular diseases in patients with T2DM.

作者简介

A Ametov

Russian Medical Academy of Postgraduate Education, Russian Agency for Health Care, Moscow

Кафедра эндокринологии и диабетологии с курсом эндокринной хирургиид-р мед. наук, проф., зав. каф; ГОУ ДПО РМАПО Росздрава; Russian Medical Academy of Postgraduate Education, Russian Agency for Health Care, Moscow

O Pyanykh

Russian Medical Academy of Postgraduate Education, Russian Agency for Health Care, Moscow

Email: doctor-olgap@mail.ru
Кафедра эндокринологии и диабетологии с курсом эндокринной хирургииаспирант; ГОУ ДПО РМАПО Росздрава; Russian Medical Academy of Postgraduate Education, Russian Agency for Health Care, Moscow

N Chernikova

Russian Medical Academy of Postgraduate Education, Russian Agency for Health Care, Moscow

Кафедра эндокринологии и диабетологии с курсом эндокринной хирургииканд. мед. наук, доц; ГОУ ДПО РМАПО Росздрава; Russian Medical Academy of Postgraduate Education, Russian Agency for Health Care, Moscow

参考

  1. American Diabetes Association; National Heart, Lung and Blood Institute; American Heart Association. Diabetes mellitus: a major risk factor for cardiovascular disease. Circulation 1999; 100: 1132-1133.
  2. Juutilainen A. Gender difference in the impact of type 2 diabetes on coronary heart disease risk. Diabet. Care 2004; 27: 2898-2904.
  3. IDF (International Diabetes Federation). Diabetes atlas. 3-rd ed. Brussels: International Diabetes Federation 2006. 5.
  4. Roglic G., Unwin N., Bennett P. H. et al. The burden of mortality attributable to diabetes: realistic.estimates for the year 2000. Diabet. Care 2004; 28: 2130-2135.
  5. Gray R. P., Yudkin J. S. Textbook of diabetes. 2-nd ed. Oxford: Blackwell Sciences; 1997.
  6. Haffner S. M., Lehto S., Ronnemaa T. et al. Mortality from coronary heart deisease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 1998; 339: 229-234.
  7. Haffner S. M., D'Agostino R. J., Mykkanen L. et al. Insulin sensitivity in subjects with type 2 diabetes: relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study. Diabet. Care 1999; 22: 562-568.
  8. The Task Forсе on Diabetes and Cardiovascular Disease of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular disease: executive summary. Eur. Heart J. 2007; 28: 88-136.
  9. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br. Med. J. 1998; 317: 703-713.
  10. Adler A., Stratton I. M., Neil H. et al. Assoсiation of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. Br. Med. J. 2000; 321: 412-419.
  11. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension and of the European Society of Cardiology. 2007 guidelines for the management of arterial hypertension. J. Hypertens 2007; 25: 1105-1187.
  12. Stratton I. M., Adler A. I., Neil H. A. et al. // Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br. Med. J. 2000; 321: 405-412.
  13. Wilson P. W. F., Kannel W. B. In: Hyperglycemia, Diabetes and Vascular Diseas / Ed. By N. Ruderman et al. Oxford, 1992. 21-29.
  14. Дедов И. И., Александров А. А. Сердечно-сосудистая патология и сахарный диабет. Статины и "микрососудистая ишемия" миокарда. Consilium Medicum. 2004; 9: 4-9.
  15. Дедов И. И., Бондаренко И. З., Ахматова Ф. Д., Александров А. А. Кардиальная автономная нейропатия в диагностике ишемической болезни сердца у больных сахарным диабетом 1-го типа. Сахар. диабет 2003; 4: 2-9.
  16. Selvin E., Marinopoulos S., Berkenblit G. et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann. Intern. Med. 2004; 141: 421-431.
  17. UK Prospective Diabetes Study (UKPDS) Group.Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352 (9131): 837-853.
  18. Goede P., Lund-Andersen H., Parving H. H. et al. Effect of multifactorial intervention on mortality in tipe 2 diabetes. N. Engl. J. Med. 2008; 358: 580-589.
  19. Holman R. R., Paul S. J., Bethel M. A. et al. Ten-year follow-up after tight control of blood pressure in type 2 diabetes. N. Engl. J. Med. 2008; 359 (15); 1577-1589.
  20. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med. 2008; 358: 2545-2559.
  21. Buse J. B., Bigger J. T., Byington R. P. et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am. J. Cardiol. 2007; 99: 21i-33i.
  22. Nissen S. E. et al. Effect of Rosiglitasone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 2007; 356: 2457-2473.
  23. Duckworth W., Abraira C., Moritz T. et al. Glucose control and vascular complications in veterans with type 2 diabetes. N. Engl. J. Med. 2009; 360: 129-139.
  24. ADVANCE Collaborative Group/ADVANCE - Action in diabetes and vascular disease: patient recruitment and characteristics of the study population at baseline. Diabet. Med. 2005; 22: 882-888.
  25. Dluhy R. G., McMahon G. T. Intensive Glycemic Control in the ACCORD and ADVANCE Trials. N. Engl. J. Med. 2008; 358: 2630-2633.
  26. ADVANCE trial: a randomized controlled trial. Lancet 2007; 370: 829-840.
  27. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 2008; 358: 2560-2572.
  28. Fuchtenbusch M., Hummel M. Intensive blood sugar treatment in type 2 diabetics: no evidence for increased mortality in the ADVANCE study compared with ACCORD study. MMW Fortschr. Med. 2008; 150 (17): 42-44.
  29. ACCORD Study Group. Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med. 2008; 358: 2545-2559.
  30. ADVANCE Collaborative Group. Study rationale and design of the ADVANCE Study: a randomised trial of blood pressure lowering and intensive glucose control in high risk individuals with type 2 diabetes mellitus. J. Hypertens. 2001; 19 (suppl. 4): S21-S28
  31. Duckworth W., Abraira C., Moritz T. et al. VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N. Engl. J. Med. 2009; 360: 129-139.
  32. Ray K. K. et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analisis of randomized controlled trials. Lancet 2009; 373: 1765-1772.
  33. Cefalu W. T. Glycemic targets and cardiovascular disease. N. Engl. J. Med. 2008; 358: 2633-2635.
  34. Karalliedde J., Gnudi L. ACCORD and ADVANCE: a tale of two studies on the Merits control in type 2 diabetic patients. Nephrol. Dial. Transplant. 2008; 23 (6): 1796-1798.
  35. Soo Yeon S., Nesto R. W. Implications of intensive glycemic control on cardiovascular disease: early reports from the ACCORD and ADVANCE Trials. Rev. Cardiovasc. Med. 2008; 9 (1): 1-4.
  36. Radermecker R. P., Philips J. C., Jandrain B. et al. Blood glucose control and cardiovascular disease in patients with type 2 diabetes. Results of ACCORD, ADVANCE and VA-Diabetes trials. Rev. Med. Liege 2008; 63 (7-8): 511-518.
  37. ADVANCE Management Committee. Study Rational and Design of ADVANCE: Action in diabetes and vascular disease- preterax nad diamicron MR controlled evaluation. Diabetologia 2001; 44: 1118-1120.
  38. Ismail-Beigi, Moghissi E. S. Glycemia management and cardiovascular risk in type 2 diabetes: an evolving perspective. Endocr. Pract. 2008; 14 (5): 639-643.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Consilium Medicum, 2010

Creative Commons License
此作品已接受知识共享署名-非商业性使用-相同方式共享 4.0国际许可协议的许可。
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


##common.cookie##